Clinigen Group extends partnership with BTG

AIM-listed pharmaceutical Clinigen Group’s Idis Global Access division extended its four-year partnership with BTG, a healthcare company, to manage its critical care portfolio across the whole of Europe and new territories in Asia.

The agreement now includes all of Europe and some emerging markets in southeast Asia to supply a managed access programme for healthcare professionals to access BTG's antidote products for patients who have no other treatment options available, such as Voraxaze, a treatment of toxic plasma methotrexate concentrations in the blood caused by high-dose methotrexate chemotherapy.

It also includes supplying DigiFab, a treatment for patients with life-threatening or potentially life-threatening digoxin toxicity, in the UK on a commercial basis.

The company said the partnership builds on the company’s international footprint following the acquisition of Link Healthcare in 2015.

Steve Glass, chief commercial officer of North America and Europe, at Clinigen said: "This is a notable exclusive supply agreement for Idis Global Access. It not only expands our existing partnership with BTG but it is also the first agreement that capitalises on the complementary nature of our managed access and global access divisions.

“It demonstrates the value of our unique, synergistic businesses which enables us to provide safe and ethical access to a medicine throughout its lifecycle - from development to approval, to launch and beyond.”

Shares in Clinigen Group were up 1.05% to 746.25p at 0913 BST.